WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: VIGL), a clinical-stage biotechnology company committed to ...
Research from VIB-UGent identifies lipid-associated macrophages and LAM-like Kupffer cells as critical for liver repair. The ...
Vigil posted positive phase 1 results for VG-3927, but competitor Alector's failure raises concerns about phase 2. Click here ...
Our livers contain many different types of immune cells. New research by the team of Prof. Charlotte Scott (VIB-UGent Center ...
Vigil Neuroscience advances VG-3927, a small molecule TREM2 agonist, into Phase II Alzheimer’s trials in Q3 2025 following ...
News Medical on MSN5d
Key immune cells required for tissue repair following liver injuryOur livers contain many different types of immune cells. New research by the team of Prof. Charlotte Scott (VIB-UGent Center ...
Vigil Neuroscience, Inc., a clinical-stage biotechnology company listed on the Nasdaq under the symbol VIGL, recently unveiled promising results from its Phase 1 clinical trial for the experimental ...
Ncardia, a global leader in human induced pluripotent stem cell (hiPSC) technology, today announced the launch of Ncyte® ...
Hosted on MSN2d
Research Identifies Key Immune Cells for Liver RepairOur livers contain many different types of immune cells. New research by the team of Prof. Charlotte Scott (VIB-UGent Center ...
News Medical on MSN6d
Study reveals sex-specific differences in microglial response to CSF1R inhibitionResearchers investigate the sex-dependent microglial response to a colony-stimulating factor 1 receptor (CSF1R) inhibitor.
The company is also running mid-stage trials of ABBV-552, an SV2A modulator, which is being evaluated to enhance synaptic efficiency in Alzheimer's, and Alector-partnered TREM2-directed antibody ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback